Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 (sacubitril/valsartan) vs enalapril in pediatric heart failure with systemic left ventricular systolic dysfunction
jRCT2080223850Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in chronic heart failure (CHF) (4 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability of LCZ696 in pediatric heart failure (Part 1), Pharmacokinetics of LCZ696 in pediatric patients (Part 1) and 1 more. Started Mar 2018; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on jRCT2080223850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223850.